Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887048 | 0.87 | LMNA (0.42) | LMNAACHEMAPTTSHR | |
| SCHEMBL6886661 | 0.84 | CYP1A2 (0.37) | LMNAACHEMAPTTSHR | |
| SCHEMBL6882634 | 0.83 | LMNA (0.36) | LMNAACHE | |
| SCHEMBL6885714 | 0.83 | ACHE (0.35) | ACHEMAPTTSHR | |
| SCHEMBL6880435 | 0.81 | LMNA (0.34) | LMNA | |
| SCHEMBL6880390 | 0.80 | LMNA (0.33) | LMNA | |
| SCHEMBL18655567 | 0.78 | TDP1 (0.39) | ACHE | |
| SCHEMBL18655553 | 0.76 | ACHE (0.36) | ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL18757104 | 0.75 | ACHE (0.35) | ACHE | |
| SCHEMBL3953134 | 0.73 | ALDH1A1 (0.34) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | MULVIHILL MARK JOSEPH (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | LMNA 1992/4885ACHE 2288/4885MAPT 2094/4885 |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | DDT, CYP4X1, CYP1B1 | LMNA 3227/4885ACHE 48/4885MAPT 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.